Limits...
Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis.

Neyt M, Hulstaert F, Gyselaers W - BMJ Open (2014)

Bottom Line: A cost-consequences analysis was performed presenting the impact on benefits, harms and costs.Introducing NIPT in the first or second line reduces harm by decreasing the number of procedure-related miscarriages after invasive testing.In Belgium, the introduction and reimbursement of NIPT as a second line triage test significantly reduces procedure-related miscarriages without increasing the short-term screening costs.

View Article: PubMed Central - PubMed

Affiliation: Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium.

Show MeSH

Related in: MedlinePlus

Presentation of most relevant screening scenarios. See the discussion for further explanation on the interpretation of the line presenting the ‘average cost per T21 detected (current screening)’. Remark: this figure does not present other outcomes of importance, such as the number of procedure-related miscarriages (NIPT, non-invasive prenatal test; T21, trisomy 21).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4225226&req=5

BMJOPEN2014005922F2: Presentation of most relevant screening scenarios. See the discussion for further explanation on the interpretation of the line presenting the ‘average cost per T21 detected (current screening)’. Remark: this figure does not present other outcomes of importance, such as the number of procedure-related miscarriages (NIPT, non-invasive prenatal test; T21, trisomy 21).

Mentions: Figure 2 provides an overview of the most relevant scenarios, including the impact of uncertainty of all input variables. The x-axis and y-axis represent the number of T21 diagnoses and total short-term costs, respectively. We remark that these are not the only outcomes of importance. Other outcomes, such as the number of procedure-related miscarriages, should also be taken into consideration. Further details on all outcomes are mentioned in online supplementary tables.


Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis.

Neyt M, Hulstaert F, Gyselaers W - BMJ Open (2014)

Presentation of most relevant screening scenarios. See the discussion for further explanation on the interpretation of the line presenting the ‘average cost per T21 detected (current screening)’. Remark: this figure does not present other outcomes of importance, such as the number of procedure-related miscarriages (NIPT, non-invasive prenatal test; T21, trisomy 21).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4225226&req=5

BMJOPEN2014005922F2: Presentation of most relevant screening scenarios. See the discussion for further explanation on the interpretation of the line presenting the ‘average cost per T21 detected (current screening)’. Remark: this figure does not present other outcomes of importance, such as the number of procedure-related miscarriages (NIPT, non-invasive prenatal test; T21, trisomy 21).
Mentions: Figure 2 provides an overview of the most relevant scenarios, including the impact of uncertainty of all input variables. The x-axis and y-axis represent the number of T21 diagnoses and total short-term costs, respectively. We remark that these are not the only outcomes of importance. Other outcomes, such as the number of procedure-related miscarriages, should also be taken into consideration. Further details on all outcomes are mentioned in online supplementary tables.

Bottom Line: A cost-consequences analysis was performed presenting the impact on benefits, harms and costs.Introducing NIPT in the first or second line reduces harm by decreasing the number of procedure-related miscarriages after invasive testing.In Belgium, the introduction and reimbursement of NIPT as a second line triage test significantly reduces procedure-related miscarriages without increasing the short-term screening costs.

View Article: PubMed Central - PubMed

Affiliation: Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium.

Show MeSH
Related in: MedlinePlus